Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (401)	1/26/2000 11:06:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 804

New PDE-4 classes inhibitors {2-[1-(3-ethoxy-4-methoxyphenyl)-2-(N,N-dimethylaminosulfonyl)ethyl]isoindolin-1-one, 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7 tetrafluoroisoindoline, 2-(2,6-dioxoethylpiperidin-3-yl)-4-aminophthalimide, 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-aminoisoindoline- 1,3-dione,... and their structure analogues), or SelCIDs: United States Patent 6,011,050 Muller , et al. January 4, 2000 -------------------------------------------------------------------------------- Substituted phenethylsulfones and method of reducing TNF.alpha. levels Abstract Phenethylsulfones substituted in the position .alpha. to the phenyl group with a 1-oxoisoindoline or 1,3-dioxoisoindoline group reduce the levels of TNF.alpha. in a mammal. Typical embodiments are 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-aminoisoindoline- 1,3-dione and 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-methylsulfonylethyl]isoindoline- 1,3-dione. -------------------------------------------------------------------------------- Inventors: Muller; George W. (Bridgewater, NJ); Man; Hon-Wah (Neshanic Station, NJ) Assignee: Celgene Corporation (Warren, NJ) Appl. No.: 340617 Filed: June 29, 1999 6 months from application filed to issued patent. They do not waste time??? Miljenko